196 related articles for article (PubMed ID: 24606321)
1. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
Meijers WC; van der Velde AR; de Boer RA
Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
[TBL] [Abstract][Full Text] [Related]
2. Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failure.
Gruson D; Mancini M; Ahn SA; Rousseau MF
Clin Biochem; 2014 Aug; 47(12):1006-9. PubMed ID: 24925289
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive review of the prognostic value of galectin-3 in heart failure.
Coburn E; Frishman W
Cardiol Rev; 2014; 22(4):171-5. PubMed ID: 24407048
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.
McCullough PA; Olobatoke A; Vanhecke TE
Rev Cardiovasc Med; 2011; 12(4):200-10. PubMed ID: 22249510
[TBL] [Abstract][Full Text] [Related]
5. Soluble ST2 and galectin-3 in heart failure.
Shah RV; Januzzi JL
Clin Lab Med; 2014 Mar; 34(1):87-97, vi-vii. PubMed ID: 24507789
[TBL] [Abstract][Full Text] [Related]
6. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction.
Gruson D; Mancini M; Ahn SA; Rousseau MF
Clin Chim Acta; 2014 Feb; 429():189-93. PubMed ID: 24365381
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 in heart failure with preserved ejection fraction.
de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
[TBL] [Abstract][Full Text] [Related]
8. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
[TBL] [Abstract][Full Text] [Related]
9. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
[TBL] [Abstract][Full Text] [Related]
11. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
[TBL] [Abstract][Full Text] [Related]
12. Novel biomarkers for heart failure.
Iqbal N; Alim KS; Aramin H; Iqbal F; Green E; Higginbotham E; Maisel AS
Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1155-69. PubMed ID: 23980627
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
Leone M; Iacoviello M
Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3: a novel mediator of heart failure development and progression.
de Boer RA; Voors AA; Muntendam P; van Gilst WH; van Veldhuisen DJ
Eur J Heart Fail; 2009 Sep; 11(9):811-7. PubMed ID: 19648160
[TBL] [Abstract][Full Text] [Related]
15. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
[TBL] [Abstract][Full Text] [Related]
16. Fibrosis in heart failure subtypes.
Toprak G; Yüksel H; Demirpençe Ö; Islamoglu Y; Evliyaoglu O; Mete N
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2302-9. PubMed ID: 24065222
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
Gehlken C; Suthahar N; Meijers WC; de Boer RA
Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
[TBL] [Abstract][Full Text] [Related]
18. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments.
Gaze DC; Prante C; Dreier J; Knabbe C; Collet C; Launay JM; Franekova J; Jabor A; Lennartz L; Shih J; del Rey JM; Zaninotto M; Plebani M; Collinson PO
Clin Chem Lab Med; 2014 Jun; 52(6):919-26. PubMed ID: 24445238
[TBL] [Abstract][Full Text] [Related]
19. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
[TBL] [Abstract][Full Text] [Related]
20. Newer biomarkers in heart failure.
Gupta S; Drazner MH; de Lemos JA
Heart Fail Clin; 2009 Oct; 5(4):579-88. PubMed ID: 19631181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
